Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer - Top-Institutions - MDSpire

Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer

  • By

  • Soraia Lobo-Martins

  • Diogo Martins-Branco

  • Francine Padonou

  • Hafid Dahma

  • Sigi van den Wijngaert

  • Mounia Jaouart

  • Chiara Dauccia

  • Chiara Molinelli

  • Elisa Agostinetto

  • Angela Loizidou

  • Donatienne Taylor

  • Anais Boisson

  • Soizic Garaud

  • Chloé Spilleboudt

  • Jose Vicente Cardona

  • Peter Ramge

  • Bogdana Ioana Balas

  • Mohammed Bajji

  • Fanny George

  • Tabatha Delsaute

  • Marianne Paesmans

  • Lieveke Ameye

  • Martine Piccart

  • Evandro de Azambuja

  • Karen Willard-Gallo

  • May 20, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    I-SPARC
    I-SPARC

    Unknown, Unknown

    Key Differentiators

    • Oncology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #3

    The Royal Marsden Hospital NHS Foundation Trust
    The Royal Marsden Hospital NHS Foundation Trust

    London, England

    Key Differentiators

    • Oncology

  • #4

    The Francis Crick Institute
    The Francis Crick Institute

    London, England

    Key Differentiators

    • Oncology

  • #5

    Emory University School of Medicine
    Emory University School of Medicine

    Atlanta, GA

    Key Differentiators

    • Oncology

Original Source(s)

Long-term immune response to mRNA anti-SARS-CoV-2 vaccination in patients with cancer

  • by Soraia Lobo-Martins, Diogo Martins-Branco, Francine Padonou, Hafid Dahma, Sigi van den Wijngaert, Mounia Jaouart, Chiara Dauccia, Chiara Molinelli, Elisa Agostinetto, Angela Loizidou, Donatienne Taylor, Anais Boisson, Soizic Garaud, Chloé Spilleboudt, Jose Vicente Cardona, Peter Ramge, Bogdana Ioana Balas, Mohammed Bajji, Fanny George, Tabatha Delsaute, Marianne Paesmans, Lieveke Ameye, Martine Piccart, Evandro de Azambuja, Karen Willard-Gallo

  • May 20, 2026

Related Content

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen